The mission of the UCSF-GIVI CFAR is to promote multidisciplinary research at the intersection of the basic, clinical and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's Center for AIDS Prevention Studies (CAPS) to coordinate a multi-pronged program that includes: 1) providing scientific leadership and direction through a proactive planning process that identifies the most important challenges emerging at the leading edge of HIV research; 2) assembling research teams across different disciplines and sites to address all dimensions of these identified challenges; 3) maintaining an outstanding set of scientific cores that extends the scientific reach of Center investigators; 4) ensuring a highly skilled, ethnically diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring and pilot grants program unique at UCSF; 5) directing CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest; 6) engaging the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership and 7) ensuring our programs are closely aligned with the NIH's AIDS programs, OAR's strategic plan for HIV/AIDS, and the President's National Strategy for HIV/AIDS. CFAR brings value by creafing and sustaining a true community of HIV/AIDS science. CFAR seeks transparency, discipline and inclusiveness in all of its operations and programs. CFAR is proud of its accomplishments in the last four years including publication of 1,172 papers, the mentoring of 44 early career investigators, the award of $4.1 million in CFAR grants and supplements to 85 scientists, the success of CFAR investigators in winning $135 million dollars in peer-reviewed, HIV related funding, and the planning and organization of the first Sub-Saharan Africa CFAR Conference that featured the work of African scientists from 13 countries and will help to build effective South-South collaborations. However, much work remains to be done. CFAR looks forward to helping stimulate progress on multiple scientific fronts including HIV and Aging, HIV eradication, increasing access to proven biomedical approaches to HIV prevention including chemoprophylaxis and reducing community viral load, and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Public Health Relevance

The UCSF-GIVI CFAR is dedicated to promoting multidisciplinary research to accelerate progress in answering the important questions emerging in HIV/AIDS biology, treatment, and preven2ion. This approach has led to breakthrough discoveries advancing patient care and providing new approaches for curbing HIV infection in the United States and at international sites. CFAR is also committed to identifying and supporting the next generation of HIV investigators who are critical for truly ending the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
4P30AI027763-25
Application #
9122283
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
25
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Tang, Weiming; Liu, Chuncheng; Cao, Bolin et al. (2018) Receiving HIV Serostatus Disclosure from Partners Before Sex: Results from an Online Survey of Chinese Men Who Have Sex with Men. AIDS Behav 22:3826-3835
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Tamraz, Bani; Huang, Yong; French, Audrey L et al. (2018) A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clin Pharmacol Ther 104:949-956
Clutton, Genevieve Tyndale; Jones, R Brad (2018) Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol 9:1452
Kattah, Michael G; Milush, Jeffrey M; Burt, Trevor et al. (2018) Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 9:143
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
El-Sadr, Wafaa M; Goosby, Eric (2018) Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV. AIDS 32 Suppl 1:S1-S3
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Dunkley, Emma; Ashaba, Scholastic; Burns, Bridget et al. (2018) ""I beg you…breastfeed the baby, things changed"": infant feeding experiences among Ugandan mothers living with HIV in the context of evolving guidelines to prevent postnatal transmission. BMC Public Health 18:188
Streubel, Gundula; Watson, Ariane; Jammula, Sri Ganesh et al. (2018) The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. Mol Cell 70:371-379.e5

Showing the most recent 10 out of 1541 publications